IRWD — Ironwood Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.23bn
- $1.84bn
- $442.74m
- 26
- 39
- 46
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.98 | ||
| PEG Ratio (f) | 1.97 | ||
| EPS Growth (f) | 5.9% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -484.91% | ||
| Return on Equity | -654.88% | ||
| Operating Margin | -213.54% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 428.41 | 389.52 | 413.75 | 410.6 | 442.74 | 448.27 | 488.2 | 5.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +34.59 | +332.22 | -70.02 | -29.81 | +0.85 | +18.48 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.
Directors
- Julie Mchugh CHM (56)
- Thomas McCourt PRE (64)
- Sravan Emany CFO (44)
- Jason Rickard COO (50)
- John Minardo SVP
- Michael Shetzline SVP (62)
- Ronald Silver CAO (39)
- Mark Currie DRC (66)
- Alexander Denner IND (51)
- Andrew Dreyfus IND (62)
- Jon Duane IND (62)
- Marla Kessler IND (51)
- Catherine Moukheibir IND (62)
- Lawrence Olanoff IND (69)
- Edward Owens IND (74)
- Jay Shepard IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 5th, 1998
- Public Since
- February 3rd, 2010
- No. of Shareholders
- 29
- No. of Employees
- 267
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 156,528,648
- Address
- 100 Summer Street, Suite 2300, BOSTON, 02110
- Web
- https://www.ironwoodpharma.com/
- Phone
- +1 6176217722
- Contact
- Matt Roache
- Auditors
- Ernst & Young LLP
Upcoming Events for IRWD
Ironwood Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Ironwood Pharmaceuticals Inc Earnings Release
Similar to IRWD
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Ironwood Pharmaceuticals share price?
As of Today at 19:11 UTC, shares in Ironwood Pharmaceuticals are trading at $7.88. This share price information is delayed by 15 minutes.
How has the Ironwood Pharmaceuticals share price performed this year?
Shares in Ironwood Pharmaceuticals last closed at $7.88 and the price had moved by -29.01% over the past 365 days. In terms of relative price strength the Ironwood Pharmaceuticals share price has underperformed the S&P500 Index by -42.67% over the past year.
What are the analyst and broker recommendations for Ironwood Pharmaceuticals?
The overall consensus recommendation for Ironwood Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ironwood Pharmaceuticals dividend yield?
Ironwood Pharmaceuticals does not currently pay a dividend.
Does Ironwood Pharmaceuticals pay a dividend?
Ironwood Pharmaceuticals does not currently pay a dividend.
When does Ironwood Pharmaceuticals next pay dividends?
Ironwood Pharmaceuticals does not currently pay a dividend.
How do I buy Ironwood Pharmaceuticals shares?
To buy shares in Ironwood Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ironwood Pharmaceuticals?
As of the previous close price of $7.88, shares in Ironwood Pharmaceuticals had a market capitalisation of $1.23bn.
Where are Ironwood Pharmaceuticals shares listed?
Here are the trading details for Ironwood Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IRWD
What kind of share is Ironwood Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Ironwood Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ironwood Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Ironwood Pharmaceuticals is $18.00. That is 128.43% above the last closing price of $7.88.
Analysts covering Ironwood Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.68 for the next financial year.
What is the trend in the Ironwood Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ironwood Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -28.06%.
As of the last closing price of $7.88, shares in Ironwood Pharmaceuticals were trading -24.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ironwood Pharmaceuticals PE Ratio?
The Ironwood Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 10.98. The shares last closed at $7.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals' management team is headed by:
- Julie Mchugh - CHM
- Thomas McCourt - PRE
- Sravan Emany - CFO
- Jason Rickard - COO
- John Minardo - SVP
- Michael Shetzline - SVP
- Ronald Silver - CAO
- Mark Currie - DRC
- Alexander Denner - IND
- Andrew Dreyfus - IND
- Jon Duane - IND
- Marla Kessler - IND
- Catherine Moukheibir - IND
- Lawrence Olanoff - IND
- Edward Owens - IND
- Jay Shepard - IND